Journal News

Pan-kinase inhibitor for head and neck cancer enters clinical trials

Andrea Lius
March 18, 2025

Protein kinases, enzymes that catalyze reversible phosphorylation, are important players in cell signaling and are often dysregulated in cancer. For this reason, kinase inhibitors are popular cancer drugs that work by locking kinases in their active or inactive form, depending on function.

Kinase inhibitors that act on the active conformation, also known as adenosine triphosphate, or ATP,–competitive inhibitors, occupy the ATP binding pocket of the kinase domain, where the catalytic reaction takes place, and lock kinases in an active form. Because kinase domains across various proteins are well conserved, scientists can relatively easily develop ATP–competitive inhibitors that bind a variety of kinase targets.

3d illustration of throat cancer.
 

However, these inhibitors can be less effective than their counterparts that bind to other parts of the kinase and lock them in the inactive conformation. Binding to the ATP pocket only inhibits their enzymatic activity, but not their other functions like scaffolding, which may promote tumorigenesis. 

In a recent study published in the Journal of Biological Chemistry, an international group of scientists reported a new kinase inhibitor, NXP900, that targets the inactive form of Src family kinases, or SFKs. The team showed that head and neck as well as esophageal squamous cell carcinomas are highly sensitive to NXP900 treatment both in cell culture and animals. The drug is currently in early-stage clinical trials.  

“It was surprising to me how responsive a lot of these cell lines were to NXP900,” John Brognard, senior investigator at the National Institutes of Health’s National Cancer Institute and the study’s corresponding author, said.

Brognard said his group became interested in head and neck as well as esophageal squamous cell carcinomas because these cancers have a shared genetic component: sequence amplification of an SFK called Yes. Existing SFK Src kinase inhibitors like Dasatinib are ineffective and approved immunotherapies like Pembrolizumab have very low success rates in these types of cancer. So, patients are stuck with radiotherapy or chemotherapy, which can produce many unpleasant side effects.

Patients with these conditions are desperate for effective treatments, he said.

“One of the biggest discoveries of this paper was how we identified a patient cohort that could really benefit from NXP900,” Brognard said.

Sweta Dash, a postdoctoral fellow at NCI and lead author of the paper, and Brognard said that NXP900 targets multiple members of the SFK, including Yes, Src and Lck. According to Brognard, this approach, commonly referred to as “polypharmacology,” goes a step further beyond simple kinase inhibitors.  

Kinases that are closely related can compensate for each other and drive drug resistance, Brognard said. For example, if we target Yes alone, we will likely observe resistance arising through compensation by other SFKs like Src or Lck, he said.

“Resistance will probably eventually still occur,” said Brognard. “But we can postpone it by targeting multiple cancer drivers simultaneously.”

Dash said that future research will home in on the molecular mechanisms of NXP900.

“We saw that some of the squamous cell carcinoma lines that we tested were sensitive to NXP900 while others were resistant,” she said. “We want to know why.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Andrea Lius

Andrea Lius is a Ph.D. candidate in the Ong quantitative biology lab at the University of Washington. She is an ASBMB Today volunteer contributor.

Related articles

From the journals: JBC
Ken Farabaugh
From the journals: JBC
Emily Ulrich
From the journals: JBC
Emily Ulrich

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Sweet secrets of sperm glycosylation
Journal News

Sweet secrets of sperm glycosylation

March 12, 2025

Scientists from Utrecht University uncover similar glycosylation patterns in sperm from bulls, boars and humans, distinct from those found in blood across species. These findings may improve IVF and farming techniques.

From the Journals: JLR
Journal News

From the Journals: JLR

March 11, 2025

Promising therapeutic candidate for steatosis. Unique lipid profiles in glycogen storage disease. Microglial lactic acid mediates neuroinflammation. Read about these recent papers.

Meet Robert Helsley
Interview

Meet Robert Helsley

March 6, 2025

The Journal of Lipid Research junior associate editor studies chronic liver disease and was the first in his family to attend college.

From the Journals: MCP
Journal News

From the Journals: MCP

March 4, 2025

Protein acetylation helps plants adapt to light. Mapping protein locations in 3D tissues. Demystifying the glycan–protein interactome. Read about these recent papers.

Exploring life’s blueprint: Gene expression in development and evolution
In-person Conference

Exploring life’s blueprint: Gene expression in development and evolution

March 3, 2025

Meet Julia Zeitlinger and David Arnosti — two co-chairs of the ASBMB’s 2025 meeting on gene expression, to be held June 26-29, in Kansas City, Missouri.

From the journals: JLR
Journal News

From the journals: JLR

Feb. 27, 2025

Protein analysis of dopaminergic neurons. Predicting immunotherapy responses in lung cancer. ZASP: An efficient proteomics sample prep method. Read about papers on these topics recently published in Molecular & Cellular Proteomics.